The Recombinant Human FGL1 Protein manufactured by Seafrom is suitable for immune regulation and cancer therapy. Fibrinogen-like protein 1 (FGL1), also known as HP-041, Hepassocin, HFREP-1, and LFIRE-1, has been recognized for its protective effect in liver injury. Recent studies have indicated that FGL1 may serve as a predictor for gastric cancer (GC) patients and represent a potential target for GC therapy. Immunocytochemical studies have revealed that FGL1 selectively binds to defective spermatozoa in the cauda epididymidis. Further analyses, including Northern blot analysis and in situ hybridization, have demonstrated high expression of FGL1 in the principal cells of the proximal cauda epididymidis. In the context of fibrotic lung tissues, immunofluorescence analysis suggests increased expressions of Gtse1 and Fgl1 in fibrotic regions. Gtse1 and Fgl1 are proposed as novel targets for radiation-induced lung fibrosis. The lyophilized form of FGL1 can be stored at 4°C for 24 months, and the reconstituted liquid can be stored at -20°C for 6-12 months, avoiding repeated freeze-thaw cycles.
Specification
Expression Host: Human HEK293 cells Source: Human Synonyms: FGL1, Hepassocin, HP-041, HFREP-1, LFIRE-1, HFREP1 Protein Sequence: The DNA sequence encodes human FGL1(Q08830-1), expressed with a His tag at the C-terminus. Molecular Weight: Recombinant human FGL1 protein contains 295 amino acids, with a predicted theoretical molecular weight of 34 kD. Purity: ≥95%, confirmed by SDS-PAGE gel and high-performance liquid chromatography (HPLC) analysis. Endotoxin: <0.1 EU/μg Biological Activity: Immobilized human LAG-3 (Fc tag) at a concentration of 20 μg/mL (100 μL/well) can bind to human FGL1 (His tag) in a linear range of 0-10 μg/mL. Purification Method: Chromatographic purification Composition: Sterile PBS (pH 7.4) freeze-dried powder containing 6% mannitol.
Recombinant Human CD28 Protein, Seafrom Recombinant Human CD16A Protein, Seafrom Recombinant Human MSLN Protein, Seafrom Recombinant Human ROR1 Protein, Seafrom